Company profile
Epilepsygtx Limited is a UK company with status active founded in 2021 based in South East England.
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
PSC05 | Transaction MzUyNTc4Nzc0MGFkaXF6a2N4
Published 07 Jun 2026 09:02
CS01 | Transaction MzUyNDA2NTQ4M2FkaXF6a2N4
Published 28 May 2026 10:56
Last confirmation statement made up date
RESOLUTIONS | Transaction WUVZQTEyM0ZhZGlxemtjeA | Paper/PDF filed
Published 29 Mar 2026 22:38
MA | Transaction MzUxMTcxMTU0OWFkaXF6a2N4 | Paper/PDF filed
Published 29 Mar 2026 22:37
RESOLUTIONS | Transaction QUVZMFcxSU9hZGlxemtjeA | Paper/PDF filed
Published 27 Mar 2026 23:52
MA | Transaction MzUxMTQ4MDkyNWFkaXF6a2N4 | Paper/PDF filed
Published 27 Mar 2026 23:49
Last accounts made up date
AD01 | Transaction MzQ0MjIwNzQ3NmFkaXF6a2N4
Published 06 Nov 2024 12:57
Company registered at Companies House
Epilepsygtx develops gene therapy for refractory epilepsy.
This is a new spinout building on our Gene therapy expertise. It was established by founders and is in the process of singing of legal documents for an initial investment from UCL Tech fund. It will have the potential to licence IP developed from this award, and benefits from our experience developing gene therapy tools.
$10M Series A raise
The company is just set up. The impact will be to consolidate a portfolio of gene therapy approaches to treat refractory epilepsy and to deliver clinical trails.
The company has supported CTA-enabling toxicity, biodistribution and efficacy studies, and is in the process of raising a Series A investment to commission manufacture of a batch of clinical grade viral vector and submit a CTA application.
